Sulfonylureas

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Findings from a Scottish national cohort study show that the use of sulfonylureas as second-line glucose-lowering therapy is not associated with elevated cardiovascular risk or all-cause mortality.

People aged 60 years or older receiving thiazolidinedione monotherapy for type 2 diabetes may have a lower risk for dementia than those taking metformin monotherapy, an observational study suggests.

A number of factors are associated with severe hypoglycemia risk in people with type 2 diabetes treated with insulin or sulfonylureas, suggests research reported at the 58th EASD Annual Meeting in Stockholm, Sweden.

Cai X et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0493-2

Wang W et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13506

Desai U et al. Diabetes Care 2018: dc170662. doi: 10.2337/dc17-0662

Qian D et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0482-5